WS #12813

From 500 msgs · 6 key-dev

AstraZeneca Q2 non-GAAP EPS tops expectations by 13.6%, driven by cancer drug sales; reaffirms full-year outlook. argenx strikes $2.2B deal to acquire Forte Biosciences at $77/share, adding anti-CD122 antibody to immunology pipeline.

AstraZeneca Q2 Beat

AstraZeneca Q2 non-GAAP EPS tops expectations by 13.6%, driven by cancer drug sales; reaffirms full-year outlook.

argenx strikes $2.2B deal to acquire Forte Biosciences at $77/share, adding anti-CD122 antibody to immunology pipeline.

Full world state #12813 →

AstraZeneca Q2 Beat — World state #12813 · River